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The symptomatology of Restless Legs Syndrome (RLS) includes periodic leg movements
during sleep (PLMS), dysesthesias, and hyperarousal. Alterations in the dopaminergic
system, a presynaptic hyperdopaminergic state, seem to be involved in PLMS,
while alterations in glutamatergic neurotransmission, a presynaptic hyperglutamatergic
state, seem to be involved in hyperarousal and also PLMS. Brain iron deficiency
(BID) is well-recognized as a main initial pathophysiological mechanism of RLS.
BID in rodents have provided a pathogenetic model of RLS that recapitulates
the biochemical alterations of the dopaminergic system of RLS, although without
PLMS-like motor abnormalities. On the other hand, BID in rodents reproduces
the circadian sleep architecture of RLS, indicating the model could provide clues
for the hyperglutamatergic state in RLS. We recently showed that BID in rodents
is associated with changes in adenosinergic transmission, with downregulation of
adenosine A1 receptors (A1R) as the most sensitive biochemical finding. It was
hypothesized that A1R downregulation leads to hypersensitive striatal glutamatergic
terminals and facilitation of striatal dopamine release. Hypersensitivity of striatal
glutamatergic terminals was demonstrated by an optogenetic-microdialysis approach
in the rodent with BID, indicating that it could represent a main pathogenetic factor
that leads to PLMS in RLS. In fact, the dopaminergic agonists pramipexole and
ropinirole and the α2δ ligand gabapentin, used in the initial symptomatic treatment of
RLS, completely counteracted optogenetically-induced glutamate release from both
normal and BID-induced hypersensitive corticostriatal glutamatergic terminals. It is
a main tenet of this essay that, in RLS, a single alteration in the adenosinergic
system, downregulation of A1R, disrupts the adenosine-dopamine-glutamate balance
uniquely controlled by adenosine and dopamine receptor heteromers in the striatum
and also the A1R-mediated inhibitory control of glutamatergic neurotransmission
in the cortex and other non-striatal brain areas, which altogether determine both
PLMS and hyperarousal. Since A1R agonists would be associated with severe
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cardiovascular effects, it was hypothesized that inhibitors of nucleoside equilibrative
transporters, such as dipyridamole, by increasing the tonic A1R activation mediated by
endogenous adenosine, could represent a new alternative therapeutic strategy for RLS.
In fact, preliminary clinical data indicate that dipyridamole can significantly improve the
symptomatology of RLS.
Keywords: Restless Legs Syndrome, periodic leg movements during sleep, hyperarousal, dopamine, glutamate,
adenosine, ENT1
BID-INDUCED ALTERATIONS IN THE
DOPAMINERGIC AND GLUTAMATERGIC
SYSTEMS IN RLS
Restless Legs Syndrome (RLS) is a very prevalent neurologic
disorder. According to the RLS Epidemiology, Symptoms and
Treatment (REST) study, 5% of US and European reported
experiencing RLS symptoms at least weekly (Allen et al.,
2005). Those symptoms include a periodic, rest-induced, mostly
nocturnal, movement-responsive urge to move the legs or
periodic leg movements during sleep (PLMS) and hyperarousal
(Allen et al., 2010; Ferri et al., 2014; Ferré et al., 2015). Thus, RLS
patients do not report sleepiness during daytime, even though
the total sleep time averages less than 5.5 h (Allen et al., 2010).
The deficits of sensorimotor integration that promote PLMS and
hyperarousal are interrelated, but there is no obvious cause-
effect relationship between the two phenomena. The interrelation
can be demonstrated in polysomnographic studies, which allows
measuring the relation between the onset and offset of the arousal
events and the concomitant onset and offset of PLMS. These
studies have shown that, although it is generally believed that
PLMS cause the arousal episodes, these precede the onset of
PLMS in more than 40% of cases (Ferré et al., 2015). However,
their tight temporal relationship suggests that both events are
dependent on a common additional mechanism.
Altered dopaminergic function seems to play an important
role in PLMS, which is empirically supported by the significant
therapeutic response to L-dopa and dopamine receptor agonists,
such as pramipexole and ropinirole (Earley et al., 2014). And it
is generally believed that because these drugs have a preferential
affinity for dopamine D3 vs. dopamine D2 receptors (D3R
and D2R, respectively), that D3R constitute a main target
responsible for their therapeutic effects (Varga et al., 2009;
Manconi et al., 2011). Nevertheless, there is also evidence
of biochemical alterations in the dopaminergic system. The
dopaminergic profile in RLS includes abnormally high levels of
the dopamine metabolite 3-ortho-methyldopa (3-OMD) in the
CSF (Allen et al., 2009), a decrease in the density of striatal D2R
and a pronounced increase in tyrosine hydroxylase activity in the
striatum and substantia nigra (Connor et al., 2009). This would
be mostly compatible with a presynaptic hyperdopaminergic state,
with downregulation of D2R being probably an adaptation
secondary to an increased basal dopaminergic tone (Earley
et al., 2014). The presence of a hyperdopaminergic state in
the basal ganglia obviously posits the question about the
mechanism involved in the therapeutic effect of dopamine
receptor agonists.
On the other hand, glutamatergic mechanisms probably play
an important role in the RLS hyperarousal component. A
magnetic resonance spectroscopy imaging study in subjects with
RLS showed a significant increase in the thalamic concentration
of glutamate (measured by the proxy variable Glx, which
represents glutamate plus glutamine), which correlated with the
time spent awake during the sleep period (Allen et al., 2013b).
These findings therefore suggest a presynaptic hyperglutamatergic
state in RLS that could underlie the hyperarousal of RLS. In fact,
glutamatergic mechanisms play a central role in the therapeutic
effects of α2δ ligands, such as gabapentin and pregabalin,
which are the main therapeutic alternative to dopaminergic
ligands for initial treatment of RLS (Garcia-Borreguero et al.,
2013). Thus, α2δ ligands bind to an auxiliary regulatory protein
(α2δ) of voltage-dependent calcium channels that preferentially
modulate neurotransmitter release from glutamatergic terminals
(Dooley et al., 2007). The α2δ ligands are most effective for
the sleep disturbances in RLS, but, although less effective than
dopaminergic agonists, they are also effective for PLMS, (Garcia-
Borreguero et al., 2014). In summary, RLS pathophysiology
seems to depend on alterations in two different, but somehow
interrelated, neurotransmitter systems, dopamine and glutamate.
The dopaminergic system is mostly related to the disturbance
in sensorimotor integration with the emergence of PLMS
and glutamate seems to be involved with both PLMS and
hyperarousal.
Brain iron deficiency (BID) is recognized as a main initial
pathophysiological mechanism in the development of RLS
(Earley et al., 2014). The association between iron deficiency
and RLS was originally described by Nordlander (1953). Further
studies showed a high prevalence of RLS symptoms in conditions
with compromise of iron availability (Allen and Earley, 2007).
The prevalence of RLS in a population of patients with iron-
deficient anemia was reported to be as high as 31.5% (Allen
et al., 2013a), about six times higher than the prevalence for
RLS in the general population (Allen et al., 2005). Nevertheless,
most patients with RLS do not have systemic iron deficiency.
Although, as already proposed by Nordlander, RLS patients
present a specific iron insufficient state in the brain. Thus,
all studies of CNS iron have consistently shown BID in RLS
(reviewed in Earley et al., 2014). This brain-specific deficit in iron
seems to be related to a dysregulation of iron transportation
by the blood-brain barrier. Thus, postmortem studies suggest
alterations in the expression or function of iron management
proteins in the choroid plexus and brain microvasculature
(Connor et al., 2011). It would therefore be appropriate to
address RLS as a brain iron dyshomeostasis, a functional
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disorder of iron acquisition by the brain (Connor et al.,
2017). Significantly, there is clinical and experimental evidence
for a connection between BID and the alterations in the
dopaminergic system in RLS. Autopsy analysis have revealed that
the immunostaining for iron management proteins is altered in
the substantia nigra of RLS brains and the profile of proteins
responsible for iron management in the neuromelanin cells of
the substantia nigra indicate iron deficiency (Connor et al.,
2004). Furthermore, there is significant literature from animal
research that indicates a close relationship between brain iron
status and the dopaminergic system (for review, see Earley et al.,
2014).
In rodents, BID (including in the ventral midbrain) can
be consistently induced by providing a severe iron-deficient
diet during the post-weaning period. Even though it does
not show motor alterations that would imitate PLMS, the
post-weaning, diet-induced BID rodent represents a well-
accepted pathophysiological model of RLS (Connor et al.,
2009; Earley et al., 2014; Unger et al., 2014). In fact, it
provides a biological model for the understanding of the
connection of the iron and dopamine alterations in RLS, since
it reproduces the main alterations in dopaminergic transmission
observed in RLS patients. Those include an increase in striatal
extracellular concentrations of dopamine, a reduction in the
density of striatal D2R and an increased TH activity in the
ventral midbrain (Connor et al., 2009; Unger et al., 2014).
Although it does not show motor abnormalities, the BID
rodent does reproduce the circadian sleep architecture of
RLS, showing an increase in wakefulness at the end of the
awake period, which corresponds to the circadian time point
where RLS symptoms are associated with maximal disruption
of sleep (Dean et al., 2006). This implies that this model
could also provide clues for the mechanisms involved in the
hyperglutamatergic state of RLS or for alterations in other
neurotransmitter systems that could underlie the changes in
both the glutamatergic and the dopaminergic systems. A possible
candidate is adenosine and its two main receptor subtypes
in the brain, A1 and A2A receptors (A1R and A2AR). Thus,
well-known main functions of adenosine are: first, to exert a
brake in the function of the ascending dopaminergic system
by presynaptic mechanisms and by postsynaptic mechanisms
mediated by receptor complexes of specific adenosine and
dopamine receptor subtypes, the A1R-dopamine D1 receptor
(D1R) and A2AR-D2R heteromers (Ferré et al., 1997, 2016; Ginés
et al., 2000; Hillion et al., 2002; Canals et al., 2003); second,
to act as a universal A1R-mediated presynaptic inhibitor of
glutamatergic transmission (Wu and Saggau, 1997; Dunwiddie
and Masino, 2001; Cunha, 2016); third, to act as a mediator of
sleepiness induced by prolonged wakefulness, when adenosine
accumulates in the extracellular space and acts mostly on
A1R localized in basal forebrain, cortex, and hypothalamus
(McCarley, 2007; Ferré, 2010). As here reviewed, adenosine
neurotransmission can provide the link between dopamine and
glutamate mechanisms in RLS and a hypoadenosinergic state
can explain the hyperdopaminergic and hyperglutamatergic state
of RLS.
BID-INDUCED ALTERATIONS IN THE
ADENOSINERGIC SYSTEM
In view of the established functional and molecular interactions
between striatal D2R and A2AR (see below), we first investigated
possible alterations in the density or function of striatal A2AR
associated with BID in rodents. In fact, in three separate studies
we found a consistent upregulation of striatal A2AR in rats and
rodents with severe BID, which was behaviorally associated with
a higher efficacy of A2AR antagonists to produce locomotor
activation (Gulyani et al., 2009; Quiroz et al., 2010, 2016a). The
A2AR upregulation could also be reproduced in a mammalian
cell line upon exposure to an iron chelator (Gulyani et al., 2009).
But, in our most recent study, by analyzing receptor density
by Western Blot and by radioligand binding assays, we could
also demonstrate a pronounced downregulation of A1R both
in the striatum and in the cortex, together with the expected
downregulation of striatal D2R (Quiroz et al., 2016a). When
administering a less severe iron-deficient diet, still associated with
BID (as demonstrated by a significant upregulation of transferrin
receptor), the same degree of downregulation of A1R and D2R
could be observed, but not the A2AR upregulation (Quiroz et al.,
2016a). These results indicate that downregulation of A1R might
constitute a more significant clinical correlate of BID in RLS, while
changes on A2AR density would be only observed with severe BID.
In the brain, the most salient place of interactions of
dopamine, glutamate and adenosine is in the striatum, in
the striatal GABAergic medium spiny neurons (MSNs), which
constitute more than 95% of the striatal neuronal population
(Gerfen, 2004). There are two subtypes of MSNs that give rise
to the two striatal efferent pathways that connect the striatum
with the output structures of the basal ganglia, which are the
medial segment of the globus pallidus and the substantia nigra
pars reticulata (Gerfen, 2004). The direct MSN constitutes the
direct pathway, since directly connects the striatum with the
output structures and selectively expresses A1R and D1R, and
also D3R in the ventral striatum (Ferré et al., 1996, 1997;
Sokoloff and Le Foll, 2017). The indirect MSN connects the
striatum with the lateral segment of the globus pallidus and
the ventral pallidum, and selectively expresses A2AR and D2R
(Ferré et al., 1993, 1997). We have demonstrated that A1R and
D1R and A2AR and D2R form specific receptor complexes, the
A1R-D1R and A2AR-D2R heteromers (Ferré et al., 1997, 2016;
Ginés et al., 2000; Hillion et al., 2002; Canals et al., 2003). The
biochemical properties of these heteromers will be analyzed with
more detail below, but we can introduce the concept that they act
as molecular devices by which endogenous adenosine, by acting
on the respective adenosine receptor, tonically inhibits the affinity
and signaling of the respective dopamine receptor (see below and
Figure 1A).
Apart from the postsynaptic striatal A1R-D1R andA2AR-D2R
heteromers, adenosine and dopamine receptors are also localized
in the terminals of the main striatal afferents, the dopaminergic
and the glutamatergic terminals (Bamford et al., 2004; Borycz
et al., 2007; González et al., 2012) (Figure 1A). In the
glutamatergic terminals, A1R form heteromers with A2AR and
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FIGURE 1 | Adenosine and dopamine receptors in the striatal glutamatergic
and dopaminergic terminals and in the dendritic spines of the direct and
indirect medium spiny neurons (MSN). (A) With normal brain iron conditions,
extracellular concentrations of adenosine keep an inhibitory presynaptic tone
of adenosine on glutamate and dopamine transmission, mediated by A1R,
which results in a relatively low activation of the direct and indirect MSN.
(B) Downregulation of A1R induced by brain iron deficiency leads to
hypersensitive glutamatergic terminals, to disinhibition of glutamate and
dopamine release, to triatal hyperdopaminergic and hyperglutamatergic states,
which leads to an increase and decrease in the activity of the direct MSN and
indirect MSN, respectively. DA, dopamine; GLU, glutamate; ADE, adenosine.
The equilibrative nucleoside transporter ENT1 (also localized in neurons) is only
represented in the astroglial process.
D2R form heteromers with D4 receptors (Ciruela et al., 2006;
González et al., 2012; Bonaventura et al., 2017) (Figure 1A).
The A1R-A2AR heteromer acts as a concentration-dependent
switch, since adenosine has more affinity for A1R than A2AR
receptors, which activation inhibits and stimulates glutamate
release, respectively. Under basal conditions, adenosine tonically
activates predominantly A1R, which inhibits glutamate release.
A2AR is activated with higher concentrations of adenosine,
which would normally occur upon strong glutamatergic input
(which is associated to neuronal and glial co-release of ATP
and its conversion to adenosine by ectonucleotidases; Cunha,
2016). Activation of A2AR negatively modulates A1R signaling
in the heteromers and promotes the opposite, glutamate release
(Solinas et al., 2002; Borycz et al., 2007). The D2R and D4R
localized in the glutamatergic terminals and possibly forming
heteromers also play a significant role in the tonic inhibitory
modulation of striatal glutamate release by dopamine (González
et al., 2012; Bonaventura et al., 2017) (Figure 1A). A1R and
D2R are also found in dopaminergic terminals without forming
heteromers, where they also exert a tonic inhibitory modulation
of dopamine release. Glutamate also modulates local dopamine
release, as we have recently demonstrated with optogenetic-
microdialysis experiments (Quiroz et al., 2016b), by a mechanism
that seems to be mostly indirect, involving activation of
cholinergic interneurons and activation of nicotinic receptors
localized in the dopaminergic terminals (in preparation). Finally,
we should consider another player, the astrocytic process, which
is involved in the indirect production of extracellular adenosine,
by releasing ATP, and that clears up adenosine from the
extracellular space by nucleoside transporters, particularly ENT1
(Pascual et al., 2005; Parkinson et al., 2011; Dulla and Masino,
2013; Cunha, 2016) (Figure 1A).
A single alteration in the adenosinergic system,
downregulation of A1R, could explain the presynaptic
hyperdopaminergic and hyperglutamatergic states in RLS.
In particular, downregulation of A1R in the corticostriatal
glutamatergic terminals could result in an increased sensitivity of
those terminals to release glutamate (Figure 1B). These changes
recapitulate those observed in A1R knockout mice that show
a significant increase in striatal glutamatergic transmission,
due to an increased sensitivity of glutamatergic terminals
(Salmi et al., 2005). The increased sensitivity of corticostriatal
terminals would facilitate stimulated glutamate release and
also, secondarily, dopamine release, which could also be
potentiated by downregulation of A1R in the dopaminergic
terminals (Figure 1B). In the direct pathway MSN, this should
result in stronger neuronal activation, also dependent on
downregulation of A1R and disinhibition of D1R previously
forming heteromers with the A1R (Figure 1B). We have
also previously demonstrated that presynaptic A1R activity
facilitates postsynaptic A2AR signaling by keeping a low tone of
extracellular dopamine release. Thus, co-administration of A1R
and A2AR agonists leads to a significant increase in the activity
of the indirect MSN, as measured by c-fos and preproenkephalin
expression (Karcz-Kubicha et al., 2003, 2006). Therefore, in the
indirect MSN, presynaptic A1R downregulation should lead to
decreased neuronal activity. The increased dopamine release
should then lead to a reciprocal interaction in the A2AR-D2R
heteromer, by which D2R activation blocks A2AR-mediated
signaling through adenylyl cyclase (see below and Figure 1B).
Since increased activation of the direct and indirect MSN leads
to increase and decrease in motor activity, respectively (Gerfen
and Surmeier, 2011), the concomitant respective increase and
decrease in the activation of the direct and indirect MSN, could
explain the akatisia-like symptoms of PLMS. In conclusion,
one single alteration, A1R downregulation-mediated increased
sensitivity of corticostriatal terminals, could produce presynaptic
striatal hyperglutamatergic and hyperdopaminergic states, which
could be a sufficient pathophysiological mechanism to explain
PLMS in RLS. Downregulation of presynaptic D2R localized
in glutamatergic and dopaminergic terminals could also be a
significant contributing factor.
Consequently, we hypothesized that BID in rodents produces
an increased sensitivity of corticostriatal terminals to release
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glutamate. In that case, corticostriatal terminals could be
a main target for the therapeutic effect of drugs clinically
successful in RLS. We tested our hypothesis by using the
recently introduced optogenetic-microdialysis method, which
involves the use of a modified microdialysis probe with an
embedded optogenetic fiber. This method allows the delivery
of light surrounding the dialysis membrane, around the same
discrete area being sampled for extracellular concentrations of
glutamate. In addition, the device allows local perfusion by
reverse dialysis of drugs (for details, see Quiroz et al., 2016b).
In the first optogenetic-microdialysis study, we injected in the
rat prefrontal cortex an adeno-associated virus (AAV) encoding
channel-rhodopsin 2 (ChR2) fused to the yellow fluorescent
protein (YFP), which allows tracking its localization. After several
weeks, ChR2 was expressed by the corticostriatal terminals in
the ventral striatum and the implanted optogenetic-microdialysis
probe allowed measuring glutamate release by those terminals
upon light-induced depolarization. We could then demonstrate
that blockade of presynaptic A2AR by perfusion with the
A2AR antagonist MSX-3 counteracts optogenetically-induced
glutamate release (Quiroz et al., 2016b). For the experiments with
BID, we aimed at a more motor-involved striatal area, the dorsal
striatal area that receives innervation from the agranular motor
cortex. This corticostriatal projection has been anatomically
well-defined from different studies analyzing striatal neuronal
activation upon cortical-electrical stimulation (Sgambato et al.,
1998; Gerfen et al., 2002; Quiroz et al., 2006). A significant
glutamate release could be obtained in both iron-deprived
animals and controls when using a frequency of stimulation of
100Hz (Yepes et al., 2017), found to be optimal in previous
studies of cortical-electrical and striatal optogenetic stimulation
(Gerfen et al., 2002; Quiroz et al., 2006, 2016b). But decreasing the
frequency of stimulation to 60Hz did not produce a significant
glutamate release in control animals, although a significant
glutamate release could still be observed in the rats with BID
(Yepes et al., 2017). These results therefore confirmed the
hypothesis of a higher sensitivity of corticostriatal terminals to
depolarization-induced glutamate release in the rodent brain
with BID. As in our previous study, blockade of A2AR with
perfusion with MSX-3 counteracted glutamate release, both in
controls at 100Hz and in iron-deprived animals at 60Hz (Yepes
et al., 2017).
If hypersensitive corticostriatal terminals represent a main
pathogenetic mechanism of RLS, they could represent a main
target for the therapeutic effect of drugs currently used
in RLS. As initial treatment for persistent RLS, the Mayo
Clinic Recommendations include either non-ergotic dopamine
agonists, such as pramipexole and ropinirole, or α2δ ligands,
such as gabapentin; for refractory RLS, the recommendations
are combination therapy (dopamine agonist + α2δ ligands),
replenishment of iron stores or considering opioid treatment
(empirically found efficient for PLMS) (Garcia-Borreguero et al.,
2013; Silber et al., 2013). In fact, perfusion of either the α2δ ligand
gabapentin or the dopamine agonists pramipexole or ropinirole
blocked glutamate release induced by optogenetic stimulation,
both in controls (at 100Hz) and in iron-deprived animals (at
60Hz) (Yepes et al., 2017). To our knowledge, this represents the
first example of a convergence of the two different mechanisms
of action of dopaminergic and glutamatergic compounds in
the BID rodent. Subsequently, we questioned the identity of
dopamine receptor subtypes involved in the pharmacological
effect of pramipexole and ropinirole. We have recently reported
results of the optogenetic-microdialysis technique in knock-
in mice expressing the long intracellular domain of D4.7,
the product of a polymorphic variant of the D4R gene
(DRD4) associated with attention deficit hyperactivity disorder
(ADHD) and substance use disorders (SUD) (Bonaventura
et al., 2017). When compared with the wild-type mouse D4R,
the expanded intracellular domain of the humanized D4R
conferred a gain of function, blunting optogenetically-induced
corticostriatal glutamate release (Bonaventura et al., 2017).
These results confirmed a key role of striatal D4R localized
in glutamatergic terminals in the control of corticostriatal
glutamatergic transmission. Since previous studies also indicated
that D2SR (the short isoform of D2R) is also localized in
striatal glutamatergic terminals, probably forming heteromers
with D4R (González et al., 2012), we analyzed the effect
of different dopamine receptor antagonists on the effect of
pramipexole. Co-perfusion with selective D4R or D2R, but not
D3R antagonists, counteracted the effect of pramipexole and
the optogenetic stimulation could still increase glutamate release
both in controls (at 100Hz) and in iron-deprived animals (at
60Hz), therefore indicating that D4R and D2R, but not D3R
are the main targets of the inhibitory effects of dopamine
receptor agonists on striatal glutamate release (Yepes et al.,
2017).
STRIATAL ADENOSINE RECEPTOR
HETEROMERS: THE A2AR-D2R
HETEROTETRAMER
It is becoming generally accepted that GPCR receptors form
pre-coupled functional complexes that include other receptors
with the formation of receptor oligomers. The current definition
of receptor oligomer is that of “a macromolecular complex
composed of at least two (functional) receptor units (protomers)
with biochemical properties that are demonstrably different from
those of its individual components” (Ferré et al., 2009). To
understand these unique biochemical properties, we need to
understand the basis of allosterism, which is currently defined as
“the process by which the interaction of a chemical or protein at one
location on a protein or macromolecular complex (the allosteric
site) influences the binding or function of the same or another
chemical or protein at a topographically distinct site” (Smith and
Milligan, 2010). An orthosteric agonist, which binds to the same
receptor site than the endogenous transmitter, has two main
and independent properties: affinity (the avidity with which it
binds to the receptor) and intrinsic efficacy (the power with
which the agonist produces its functional response). In classical
GPCR allosterism, the allosteric ligand binds to a non-orthosteric
site and modifies either of the properties of the orthosteric
agonist. In this frame, the GPCR has been usually considered as a
monomeric entity. However, accumulating convincing evidence
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indicates that a main GPCR functional unit is constituted by one
GPCR homodimer and its cognate G protein (Ferré et al., 2014).
Allosterism in the frame of GPCR homodimers implies the
possibility of allosteric interactions between orthosteric ligands,
either the same or different ligands. The ligand binding to the
first protomer modifies either the affinity or intrinsic efficacy of
the second protomer. Cooperativity usually refers to the situation
where the ligand binding to the first protomer, decreases the
affinity of the same ligand binding to the second protomer.
But modulator and modulated ligands can also be different
orthosteric ligands, agonists or antagonists (Casadó et al., 2009;
Ferré et al., 2014). With GPCR heteromers, with two different
protomers, we also have two possibilities: first, the same ligand,
when the protomers are two different receptor subtypes, such
as dopamine D1R and D3R or D2R and D4R, or adenosine
A1R and A2AR; second, two obligatory different ligands, when
the two protomers bind different endogenous ligands, such
as A2AR and D2R or A1R and D1R (Ferré et al., 2014).
One of the first clear clues of this type of allosterism in a
GPCR heteromer was obtained from radioligand experiments
in membrane preparations from rat striatum, where adenosine
A2AR ligands were found to modulate the affinity of D2R
ligands in rat striatal membrane preparations (Ferré et al., 1991d).
In these experiments, the selective A2AR agonist CGS21680
displaced significantly to the right the competitive inhibition
curve of dopamine vs. the D2R antagonist tritiated raclopride,
indicating a decrease in the affinity of dopamine for the D2R. This
experiment also demonstrated, as simultaneously confirmed by
Schiffmann et al. (1991) from in situ hybridization experiments,
that A2AR and D2R are highly co-localized in the same striatal
neuron, the indirect MSN.
The possibility of real allosteric interactions between A2AR
and D2R ligands strongly suggested direct intermolecular
interactions between both receptors. This was later demonstrated
first in artificial systems, in mammalian cells transfected with
receptors fused to biosensors that only interact when in very
close proximity. In Bioluminescence Resonance Energy Transfer
(BRET), there is a transfer of energy from a bioluminescent
donor, Renilla luciferase (Rluc), to a fluorescent acceptor, such
as YFP, and this can only occur when both biosensors are closer
than 10 nM. In Bimolecular Fluorescence Complementation
(BiFC), two complementary halves of the fluorescent sensor
separately fused to the putative interacting receptors should
complement and reconstitute YFP and, therefore, its ability to
produce fluorescence (Canals et al., 2003; Navarro et al., 2010;
Bonaventura et al., 2015). These techniques can then be used to
determine the biochemical properties of the GPCR heteromer
and, indirectly, to allow their identification in the native tissue.
Our rationale is to identify and disrupt the heteromerization
interface, the domains of the receptors that establish intermolecular
interactions. We have in fact found evidence for discrete but
strong interactions between intracellular domains and extensive
but very specific interactions between transmembrane domains
(TMs). From in vitro experiments of peptide interactions with
mass spectrometry we found evidence for a very discrete
but powerful electrostatic interaction between an arginine-rich
domain of the third intracellular loop of the D2R and a phosphate
group from a specific serine within the tail of the A2AR (Woods
and Ferré, 2005). Transfection of receptors with mutations of
either of these residues led to a very significant reduction of
BRET (Ciruela et al., 2004; Navarro et al., 2010). In addition, the
same mutations led to the loss of the ability of the A2AR agonist
CGS21680 to decrease the affinity of the D2R agonist quinpirole,
which demonstrated that this is, in fact, an allosteric interaction
within the A2AR-D2R heteromer (Bonaventura et al., 2015).
Synthetic peptides with the amino acid sequence of the
interacting domains are becoming a very successful tool to
selectively disrupt the intermolecular interactions in GPCR
heteromers, and not only in vitro, in transfected mammalian cells,
but also in situ, in native tissues, and in vivo, in the experimental
animal. For instance, in patch-clamp experiments with slices
of the ventral striatum of mice selectively expressing green
fluorescence protein (GFP) in D2R-expressing neurons (which
allowed the identification of the indirect MSN), CGS21680 acted
as a D2R antagonist and blocked the decrease in the neuronal
excitability induced by the D2R agonist norpropylapomorphine
(NPA; Azdad et al., 2009). This D2R antagonist-like effect
of CGS 21680 was then completely counteracted by the
intracellular application of a small peptide with a sequence of
the epitope containing the interacting phosphorylated serine
of the tail of the A2AR (Azdad et al., 2009). The efficacy of
CGS21680 to counteract the effect of a high concentration
of NPA indicated that the A2AR agonist modulates not only
the affinity, but also the efficacy of the D2R agonist (Azdad
et al., 2009). These results demonstrate the very significant role
of the allosteric interaction within the A2AR-D2R heteromer
in the modulation of the function of the indirect MSN.
More recently we used peptides with amino acid sequences
of TMs to explore the involvement of the transmembrane
intermolecular interactions. First, we studied which TM-peptides
can disrupt A2AR-D2R heteromerization in vitro by BiFC
experiments (which were selected over BRET experiments
due to the significant interference of Rluc function by the
TM-peptides; Guitart et al., 2014). BiFC was selectively disrupted
by peptides with the sequence of TM 5 of A2AR and D2R,
but not with the corresponding TM7 peptides (Bonaventura
et al., 2015). Then, the same specific disrupting peptides were
used in experiments with proximity ligation assay (PLA), an
antibody-based technique which allows identification of receptor
complexes in native tissues (Trifilieff et al., 2011). Notably, the
number of complexes was significantly reduced by the specific
disrupting peptides, demonstrating the existence of A2AR-
D2R heteromers in situ, in the striatum (Bonaventura et al.,
2015).
The allosteric interaction in the A2AR-D2R heteromer that
determines the ability of A2AR agonists to act D2R antagonists
and counteract D2R-mediated decrease in the excitability of the
indirect MSN could explain many results of previous behavioral
studies, such as the ability of adenosine agonists to reduce the
locomotor activity induced by D2R agonists in reserpinized
mice or the opposite effect with adenosine receptor antagonists,
such as caffeine (Ferré et al., 1991a,b). The effect of adenosine
antagonists indicated that endogenous adenosine exerts a tonic
influence on D2R signaling through the A2AR-D2R heteromer.
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It is now becoming accepted that the psychostimulant effects of
caffeine (a non-selective A1R and A2AR antagonist) and selective
A2AR antagonists depend on the blockade of the tonic effect of
endogenous adenosine mediated by the A2AR-D2R heteromer
(Ferré, 2016). Not surprisingly, we also found that A2AR
agonists produce catalepsy, which was counteracted by adenosine
antagonists, like theophylline (Ferré et al., 1991c). But it was
also counteracted by D2R agonists, indicating the existence of a
possible reciprocal interaction, by which D2R activation decreases
the effect of A2AR activation (Ferré et al., 1991c). In fact, A2AR
and D2R are respectively coupled to Gs/olf (Gs for short) and
Gi/o proteins (Gi for short) and we would expect an antagonistic
interaction at adenylyl cyclase level, the canonical interaction by
which activation of a Gi-coupled receptor counteracts adenylyl
cyclase activation, cAMP accumulation, induced by activation
of a Gs-coupled receptor (Gilman, 1987). We explored this
possibility in mammalian cells transfected with A2AR and D2R
and found that this is the case, that the D2R agonist quinpirole
completely antagonizes CGS21680-induced cAMP accumulation
and the concomitant downstream signaling, such as an increase
in the expression of the immediate-early gene c-fos (Kull et al.,
1999). This reciprocal D2R-A2AR interaction could also explain
the ability of non-selective adenosine receptor antagonists like
caffeine and theophylline, as well as selective A2AR antagonists,
to counteract the behavioral effects of D2R antagonists, such
as catalepsy induced by haloperidol (Casas et al., 1988; Kanda
et al., 1994; Shiozaki et al., 1999; Morelli and Wardas, 2001).
This would also imply the existence of a tone of endogenous
dopamine mediated by D2R that counteracts the effects of a tone
of endogenous adenosine mediated by A2AR. The blockade of D2R
releases A2AR signaling and it is then endogenous adenosine that
produces catalepsy upon haloperidol administration. This has
been demonstrated in several ex vivo studies, where the increase
in striatal expression of c-fos induced by a D2R antagonist is
blocked by non-selective adenosine receptor antagonists and by
selective A2AR, but not A1R antagonists (see for instance Pardo
et al., 2013).
Next obvious question is how two apparently incompatible
interactions, the allosteric and the canonical interactions,
coexist, and if the canonical interaction also depends on
heteromerization. That took us to reconsider the quaternary
structure of the A2AR-D2R heteromer, since, just because of
steric hindrance, a heterodimer cannot bind simultaneously two
G proteins. We therefore established the following hypotheses:
first, that heteromers are often heterotetramers, heteromers
of homodimers coupled to their preferred G protein; second,
that the heterotetramer enables the canonical antagonistic Gs-
Gi interaction; third, that the heterotetramer gives the frame
for the pre-coupling of the two receptors involved in the
canonical interaction, their respective G proteins and the
effector adenylyl cyclase (Ferré, 2015) (Figure 2A). Using a
double complementation assay, with both BiFC and Rluc
complementation, fusing the complementary halves of the BRET
biosensors to different molecules of A2AR and D2R, we could
demonstrate that such a quaternary structure is in fact possible
in transfected cells (Bonaventura et al., 2015). Subsequently, we
have used all possible 14 TM-peptides corresponding to the
seven TMs of A2AR and the seven TMs of D2R and studied
the interface of not only A2AR and D2R, but also the A2AR
and D2R homodimers in BiFC experiments. Significantly, only
one peptide, TM6 of A2A, disrupted A2AR dimerization, and
only one peptide, TM6 of D2R, disrupted D2R dimerization.
Furthermore, again TM5, but also TM4, of both A2AR and
D2R disrupted A2AR-D2R heteromerization (Navarro et al.,
submitted). Importantly, taking into account these results, as well
as the crystal structure of the A2AR, the D3R (as homologous
to the D2R) and the β2 adrenergic receptor in complex with
Gs, computerized modeling allowed only one solution, a linear
quaternary structure of the A2AR-D2R heterotetramer, with two
internal protomers that provide the heteromeric interface and
two external protomers that couple to the alpha subunits of their
respective G protein (Navarro et al., submitted).
We have then addressed the possible dependence on
heteromerization of the A2AR-D2R canonical interaction
in striatal cells in culture, where we previously showed
that quinpirole counteracts cAMP accumulation induced by
CGS21680 (Navarro et al., 2014). First, we could demonstrate
the existence of the A2AR-D2R heteromers in the striatal
cultures with PLA. Thus, TM4 and TM5, but not TM6 or TM7,
of both A2AR and D2R disrupted the A2AR-D2R complexes
(Navarro et al., submitted). Then, only the peptides that
disrupted heteromerization disrupted the canonical interaction.
Therefore, we could confirm that the canonical interaction is
a biochemical property of the A2AR-D2R heterotetramer. In
conclusion, both the allosteric and the canonical interactions are
biochemical properties of the A2AR-D2R heterotetramer, which
acts as a molecular device that integrates the adenosinergic
and dopaminergic signals in the indirect MSN. The output is
mostly determined by the dopaminergic input (high and low for
positive and negative reward prediction errors; Ferré, 2017) and
amplified by the wining A2AR-D2R interaction, either allosteric
or canonical (Ferré, 2016, 2017). In addition, from experiments
with BRET and BiFC, fusing the biosensors to the A2AR or D2R
and to adenylcyl cyclase type 5 (AC5), we obtained evidence
for the pre-coupling of the A2AR-D2R heterotetramer, Gs and
Gi proteins and the effector adenylyl cyclase subtype 5 (AC5).
Taking into account our results with TM peptides corresponding
to the putative TMs of adenylyl cyclase, computer modeling
(now also including Gs in complex with the catalytic domains
of adenylyl cyclase) suggested that one heterotetramer can bind
two molecules of AC and that one molecule of AC can bind two
heterotetramers, allowing the formation of high-order oligomers
with alternative links of heterotetramers and AC (Navarro et al.,
submitted).
STRIATAL ADENOSINE RECEPTOR
HETEROMERS: THE A1R-A2AR AND
A1R-D1R HETEROTETRAMERS
The A2AR-D2R heterotetramer is the most studied and best
characterized GPCR heteromer. Therefore, it can then be used
as a model for establishing similarities and differences in the
biochemical properties of other GPCR heteromers. Apart from the
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FIGURE 2 | Adenosine Gs-Gi-coupled heterotetramers. (A) The A2AR-D2R
heterotetramer, constituted by homodimers of the Gs-coupled A2AR and the
Gi-coupled D2R, enables two types of reciprocal antagonistic interactions: an
allosteric interaction, by which A2AR ligands modulate the affinity and intrinsic
efficacy of D2R ligands, and a canonical interaction at the adenylyl cyclase
(AC) level, by which D2R agonists inhibit A2AR agonists-mediated AC
activation. (B) The A1R-A2AR heterotetramer, constituted by homodimers of
the Gs-coupled A2AR and the Gi-coupled A1R, enables an allosteric
interaction, by which A2AR ligands modulate the affinity and intrinsic efficacy of
A1R ligands, but does not enable a canonical interaction at the AC level; A1R
signals independently through voltage-dependent Ca2+ channels. (C) The
A1R-D1R heterotetramer, constituted by homodimers of the Gs-coupled D1R
and the Gi-coupled A1R, enables unidirectional nonreciprocal allosteric and
canonical antagonistic interactions, with A1R ligands modifying the ligand
binding properties and adenylyl cyclase activation induced by D1R agonists.
A2AR-D2R heteromer, the same tetrameric quaternary structure
has been observed for four additional striatal Gs-Gi-coupled
heteromers which could also be involved in the pathophysiology
of RLS: the A1R-A2AR heterotetramer (Ciruela et al., 2006;
Navarro et al., 2016) and the A2AR-CB1R heterotetramer
(in preparation), both localized in the striatal glutamatergic
terminals, and the D1R-D3R heterotetramers (Fiorentini et al.,
2008; Marcellino et al., 2008; Guitart et al., 2014) and the
A1R-D1R heterotetramer (in preparation), both localized in the
direct MSN. The D2SR-D4R heteromer, on the other hand, is
only coupled to Gi proteins and, so far, we do not know if
its predominant quaternary structure is dimeric or tetrameric.
As mentioned above, the A2AR-D2R heteromer is probably
indirectly involved in the dysregulation of striatal function that
leads to PLMS symptoms, related to a predominant canonical
interaction, the D2R-mediated inhibition of A2AR-mediated
signaling, associated to the presynaptic hyperdopaminergic state.
But, as also mentioned above, BID-induced downregulation of
A1R seems could be a main pathogenetic mechanism in RLS,
which should imply a more direct involvement of the A1R-
A2AR and A1R-D1R heteromers. Interestingly, the analysis of
the structure (homo and heteromeric interfaces) and biochemical
properties of the different heterotetramers discloses differences
that differ from those of the A2AR-D2R heterotetramer.
Significantly, those biochemical differences closely relate to their
properties as modulators of neuronal function (excitability,
neurotransmitter release).
As mentioned above, the A1R-A2AR heterotetramer acts
as a concentration-dependent switch, since adenosine has
more affinity for the A1R than for the A2AR, allowing low
concentrations of adenosine to inhibit and high concentrations
to stimulate striatal glutamate release, by activating A1R
and A2AR, respectively (Ciruela et al., 2006). Different from
postsynaptic receptors (see above), studies with selective
antagonists indicate that striatal presynaptic A2AR are not
tonically activated by adenosine while presynaptic A1R are
tonically activated, particularly in specific striatal compartments.
Thus, A1R antagonists increase, while A2AR antagonists do
not modify, the striatal extracellular concentration of glutamate
(Solinas et al., 2002; Borycz et al., 2007). This might be
related to the higher density of postsynaptic receptors and
also indicates that presynaptic A1R are more sensitive than
presynaptic A2AR to the variations of endogenous adenosine.
Clearly, the A1R-A2AR heteromer-mediated concentration-
dependent switch mechanism cannot be explained in the
frame of a canonical interaction at the level of adenylyl
cyclase, where the result of the activation of a Gi-coupled
receptor depends on its ability to counteract adenylyl cyclase
activation by a Gs-coupled receptor. In fact, we have obtained
evidence for the lack of existence of canonical interaction
in the A1R-A2AR heterotetramer (Navarro et al., submitted)
(Figure 2B). Thus, in the glutamatergic terminals, A1R can signal
independently of A2AR within the A1R-A2AR heteromer, most
probably by a βγ-dependent-mediated inhibition of presynaptic
voltage-dependent Ca2+ channels (Wu and Saggau, 1997;
Gonçalves and Queiroz, 2008). Yet, when reaching the right
concentration to bind A2AR, adenosine inhibits A1R function by
a negative allosteric interaction and promotes glutamate release
by activating adenylyl cyclase (Ciruela et al., 2006; Gonçalves
and Queiroz, 2008) (Figure 2B). The same mechanism has also
been described in cortical astrocytes in culture, where A1R-
A2AR heteromers modulate GABA uptake (Cristóvão-Ferreira
et al., 2013). In addition, evidence for A2AR-D2R heteromers
that modulate glutamate release has recently been obtained in
striatal astrocytes in culture (Cervetto et al., 2017). The presence
and functional significance of these astrocytic adenosine receptor
heteromers need still to be determined.
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Soon after the discovery of specific pharmacological
interactions between A2AR and D2R, similar antagonistic
interactions were observed with A1R and D1R ligands,
with A1R agonists and antagonists promoting the specific
inhibition and facilitation of D1R agonist-mediated locomotor
activation, respectively (Ferré et al., 1994, 1996). Similarly,
specific biochemical and possibly intermolecular interactions
were reported which pointed to the existence of A1R-D1R
heteromers (Ferré et al., 1998; Ginés et al., 2000), and which
would selectively modulate the function of the direct MSN
(Ferré et al., 1994, 1997, 1999). The initial studies in mammalian
transfected cells indicated the existence of both allosteric and
canonical interactions, but, different to those in the A2AR-
D2R heteromer, not reciprocal, with A1R ligands modifying
the ligand binding properties and adenylyl cyclase activation
induced by D1R agonists (Ferré et al., 1998) (Figure 2C).
Using TM peptides, BiFC and PLA experiments, we have now
obtained experimental evidence for the tetrameric structure
of A1R-D1R, for the dependence on heteromerization for the
canonical interaction and for the presence of the heteromer
in striatal tissue (Moreno et al. in preparation) and the spinal
motoneuron (Rivera-Oliver et al., submitted). The spinal
A1R-D1R heterotetamer can explain the recently demonstrated
spinally-generated caffeine-induced locomotor activation in rats
(Acevedo et al., 2016), and we put forward the hypothesis that it
can represent a mechanism involved in the spinal component of
RLS (Trenkwalder and Paulus, 2010).
TARGETING ADENOSINE
NEUROTRANSMISSION IN RLS: THE
EQUILIBRATIVE TRANSPORTER ENT1
Apart from the striatum, which could represent a main
locus for the alteration of sensory-motor integration in RLS,
involved in PLMS symptoms, hypoadenosinergic transmission
should also occur in other brain areas. In fact, as mentioned
above, we could also demonstrate downregulation of A1R
in the cortex of mice with severe and less severe BID
(Quiroz et al., 2016a). As mentioned above, adenosine is a
main mediator of sleepiness following prolonged wakefulness,
which determines its extracellular accumulation in the basal
forebrain, cortex, and hypothalamus. Upon activation of A1R,
this accumulation leads to inhibition of the cells of origin of
the corticopetal basal forebrain system (McCarley, 2007; Ferré,
2010) and the prefrontal corticofugal neurons that innervate
the cells of origin of the pontine ascending arousal systems
(Van Dort et al., 2009). Upon activation of both A1R and
A2AR, adenosine also inhibits the hypothalamic histaminergic
and orexinergic ascending arousal systems (McCarley, 2007;
Ferré, 2010). BID-mediated A1R downregulation in the basal
forebrain, cortex, and hypothalamus, could then be the main
pathophysiological mechanism responsible for the hyperarousal
and sleep disturbances of RLS. In fact, experimental data strongly
suggest that A1R is a marker of the homeostatic sleep response, of
the need for recovery of lack of sleep. This includes the rebound
sleepiness and the cumulative sleepiness after acute and chronic
sleep deprivation, respectively (Bjorness et al., 2009, 2016; Kim
et al., 2012). It has in fact been demonstrated that acute and
chronic sleep deprivation lead to A1R upregulation in the brain,
including both cortex and striatum (Elmenhorst et al., 2007,
2009; Kim et al., 2012, 2015). Finally, as mentioned above, spinal
A1R downregulation, and particularly in the motoneuron, could
decrease the D1R inhibition, by decreasing the stoichiometry of
D1R forming heteromers with D1R.
If A1R downregulation-dependent hypoadenosinergic
transmission represents a significant pathogenetic factor in RLS
and is directly or indirectly involved in the symptoms of both
PLMS and hyperarousal, administration of A1R agonist should
represent a successful therapeutic strategy. Unfortunately, A1R
agonists cannot be used as direct targets, since they produce very
significant peripheral effects, namely pronounced bradycardia
and hypotension (Schindler et al., 2005). An alternative
strategy would be to increase the adenosine tone below the
limit of activation of presynaptic A2AR, with inhibitors of
adenosine transporters or adenosine metabolism. Our initial
choice is focusing on equilibrative nucleoside transporters.
Nucleoside transporters are not only important as a mechanism
to salvage extracellular nucleosides for intracellular synthesis
of nucleotides, but they are also important as regulators of
the extracellular levels of adenosine and as providers of an
endogenous tone of adenosinergic neurotransmission mediated
by adenosine receptors. In mammals, there are two types of
nucleoside transporters, equilibrative and concentrative, which
mediate a bidirectional equilibrative transport driven by chemical
gradient and a unidirectional concentration transport driven
by sodium electrochemical gradient, respectively (Parkinson
et al., 2011). Adenosine uptake in the brain occurs primarily
by facilitated diffusion via equilibrative transporters, which
pharmacological blockade is associated with an accumulation
of adenosine in the extracellular space (Parkinson et al., 2011;
Dulla and Masino, 2013; Cunha, 2016). From the four types
of equilibrative transporters so far identified (ENT1, ENT2,
ENT3, and ENT4), ENT1 and ENT2 are the most expressed
in the brain, both by neurons and astrocytes (Parkinson et al.,
2011). Nevertheless, some studies suggest that ENT1 has a more
salient role in determining the concentration of extracellular
adenosine in the brain and its dependence on glutamate receptor
activation (Alanko et al., 2006; Bicket et al., 2016). Furthermore,
of importance for the present discussion, ENT1 (but not ENT2)
shows a regional co-localization with A1R, which supports an
important role of ENT1-mediated transport of adenosine in the
control of the neuromodulatory actions mediated by A1R in the
human brain (Jennings et al., 2001).
We can therefore deduce that ENT1 inhibitors could be useful
therapeutic agents in RLS. Importantly, some non-selective
ENT1/ENT2 inhibitors such as dipyridamole are already being
medically used for other clinical purposes. Dipyridamole is
used as an inhibitor of platelet aggregation to decrease the risk
of thromboembolic complications and recurrence of stroke in
patients known to have atherosclerotic cerebrovascular disease.
Its effect depends on a combination of mechanisms, including
cAMP accumulation in platelets induced by phosphodiesterase
inhibition and activation of A2AR by an increased extracellular
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adenosine secondary to ENT1/2 inhibition in microvascular
endothelial cells (Kim and Liao, 2008). However, the possible
use of dipyridamole (and other ENT1/ENT2 inhibitors) as a
central nervous system agent remains uncertain in view of its
reported low ability to cross the blood-brain barrier (Sollevi,
1986; Parkinson et al., 2011) and, to our knowledge, it is not
well-established if systemic administration of dipyridamole in the
experimental animal leads to behaviorally significant increases in
the extracellular levels of adenosine.
Using the classical reserpinized mice model, we evaluated
the ability of the systemic administration of dipyridamole to
promote an increase in the adenosinergic tone in the brain.
In that case, dipyridamole should counteract the locomotor
activating effects of D1R and D2R, by acting on striatal A1R-
D1R and A2AR-D2R heteromers (Ferré et al., 1991a,b, 1994),
and the effect of dipirydamol should then be counteracted by a
non-selective A1R/A2AR antagonist, like caffeine. This model,
in fact, has been very useful for the discovery of the specific
antagonistic interactions between adenosine and dopamine
receptor ligands that led to the discovery the A2AR-D2R and
A1R-D1R heteromers. As shown in Figure 3, dipyridamole, at a
minimal dose of 30mg/kg, significantly decreased the locomotor-
activating effect of equipotent doses of the D1R agonist SKF81297
and the D2R agonist quinpirole (5 mg/kg in both cases). As
expected, caffeine (30 mg/kg) did not produce a significant
effect on its own but significantly potentiated the locomotor
activation induced by either agonist. In both cases, the depressant
effect of dipyridamole was totally counteracted by caffeine
(Figure 3). The results, therefore, can entirely be explained by
the ability of systemically administered dipyridamole to promote
an increase in the basal extracellular levels of striatal adenosine
than normally exert a tonic activating effect on postsynaptic A1R-
D1R and A2AR-D2R heteromers. Also, such an increase should
be expected to increase the activation of presynaptic A1R and
hopefully restore the hyperdopaminergic and hyperglutamatergic
state in RLS patients. Optogenetic-microdialysis experiments are
in progress to demonstrate the ability of dipyridamole to inhibit
glutamatergic neurotransmission in hypersensitive corticostriatal
terminals in BID rats.
In view of the evidence for the central adenosinergic
effect of dipyridamole in reserpinized mice, we explored the
possible clinical efficacy of dipyridamole in a prospective
2-month open trial in 13 previously untreated patients diagnosed
with idiopathic RLS (García-Borreguero et al., submitted).
Therapeutic response was defined as at least a 50% improvement
in the “International RLS Scale” and the “Multiple Suggested
Immobilization Tests.” Sleep efficiency (SE%), sleep latency and
other standard scales were used to evaluate sleep dysfunction
and hyperarousal. Dipyridamole was well-tolerated and only
two patients had to discontinue at the beginning of the trial
due to dizziness. Six and four out of the thirteen patients were
full and partial responders, respectively, and only three patients
had no significant response. Importantly, not only there was a
significant effect of subjective symptoms, but also of PLMS and
sleep complaints. These are, of course, preliminary results which
could be influenced by a placebo effect and, therefore, await
confirmation by a more extensive double-blind clinical trial.
FIGURE 3 | Adenosine-dependent modulation by dipyridamole on the
locomotor activation induced by dopamine receptor agonists in reserpinized
mice. Locomotor activity in male C57BL/6J mice (20–30 g) 20 h after
administration of reserpine (5 mg/kg, s.c.; method described in detail in
Marcellino et al., 2008) induced by the D1R agonist SKF81297 (5 mg/kg, i.p.;
SKF; A) or the D2R agonist quinpirole (5 mg/kg, i.p.; QUIN; B), with or without
the previous administration of dipyridamole (10, 30 or 100 mg/kg, i.p., 15min
before SKF or QUIN; 10DIP, 30DIP, or 100DIP) or caffeine (30 mg/kg, i.p.,
30min before SKF or QUIN; CAFF). All animals received three i.p. injections,
with either drugs or the corresponding vehicle. One reserpinized group also
received caffeine without dipyridamole or dopamine agonists. The dashed line
represents the average locomotor activity of reserpinized mice receiving only
vehicle administrations. Statistical differences were analyzed by one-way
ANOVA followed by Newman-Keuls post-hoc test; *, **, and ***: p < 0.05,
p < 0.01 and p < 0.001, respectively, as compared with either SKF or QUIN.
Confirmation of the therapeutic effect of dipyridamole in RLS
would bring ENT1 inhibition as a new therapeutic approach for
RLS, offering an alternative to dopaminergic drugs and, therefore,
to their long-term complications, mainly augmentation. This
is an overall increase in symptom severity and intensity and
represents a common complication of all dopaminergic drugs,
with prevalence rates of nearly 50%, and is a common cause
of treatment failure (Earley et al., 2014; Ferré et al., 2017).
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Furthermore, our preliminary results suggest that, in contrast
to dopaminergic agonists, ENT1 inhibitors should be effective
not only for the treatment of dysesthesias and PLMS, but also
for sleep complaints and hyperarousal in RLS. In addition to
dipyridamole, there are other marketed compounds with ENT1
inhibitory activity already used at the clinical level for their
vascular relaxation and platelet inhibition (ticagrelor, dilazep)
or their anti-inflamatory effects (sulindac). The challenge would
nevertheless be to obtain new potent and selective ENT1 (or
ENT1/ENT2) inhibitors with significant brain penetration.
It conclusion, the main tenet of this essay is that a
main mechanism responsible for PLMS and hyperarousal in
RLS can be a BID-induced hypoadenosinergic state, with
downregulation of A1R. This mechanism may disrupt the
adenosine-dopamine-glutamate balance uniquely controlled by
adenosine and dopamine receptor heteromers in the striatum
and also the A1R-mediated inhibitory control of glutamatergic
neurotransmission in the cortex and other non-striatal brain
areas and in the spinal cord. We then provide preclinical
and clinical evidence for a possible new alternative therapeutic
strategy for RLS, increasing the adenosinergic tone in the CNS
with ENT1 inhibitors.
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